Stryker v. OsteoMed: Federal Circuit Affirms US10993751 Unpatentable
Stryker European Operations Holdings challenged OsteoMed’s successful invalidity action over US10993751B1, a patent covering orthopedic bone-fixation plate implants. The Federal Circuit affirmed the unpatentability finding after 688 days of appellate proceedings, leaving Stryker’s patent protection for this implant technology extinguished.
Federal Circuit seals fate of Stryker bone-plate patent after OsteoMed challenge
Stryker European Operations Holdings, LLC filed appeal no. 23-2398 at the Court of Appeals for the Federal Circuit on 19 September 2023, seeking to overturn an invalidity or cancellation finding against US10993751B1. That patent — filed under application US17/143709 — claims an orthopedic implant in the form of a plate designed to be fixed between two bone parts, a technology central to fracture fixation and reconstructive orthopaedic surgery. OsteoMed, LLC, a rival in the orthopaedic device market, was the prevailing challenger below.
The Federal Circuit issued its disposition on 7 August 2025, affirming the lower tribunal’s finding of unpatentability. An affirmance at this level means the appellate court detected no reversible legal or factual error in the decision below, leaving the invalidity determination fully intact. For Stryker, the ruling terminates enforceable rights under US10993751B1; OsteoMed and any third-party manufacturers operating in the bone-plate space are no longer constrained by that patent.
The 688-day appellate duration suggests the parties pursued full briefing rather than an early settlement or procedural shortcut, consistent with the commercial significance of orthopaedic fixation IP. What arguments Stryker raised — claim construction, obviousness, or prior art characterisation — and the specific rationale the Federal Circuit applied are not detailed in the public docket summary, making a granular assessment of the ruling’s doctrinal footprint uncertain without the full opinion.
Filing to Unpatentable in 688 days
688 days — above median for Federal Circuit patent validity appeals
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance: no reversible error found in unpatentability decision
When the Federal Circuit affirms, it is confirming that the tribunal below committed no reversible legal error — whether on claim construction, application of the obviousness standard, or prior-art fact-finding. The lower unpatentability finding is now final at this appellate level. Stryker’s remaining avenue would be a petition for rehearing en banc or certiorari to the Supreme Court, both of which face a very high bar.
Unpatentability standingStryker loses enforceable rights under US10993751B1
With affirmance, US10993751B1 is confirmed unpatentable, meaning Stryker cannot assert it against any party. Any pending infringement actions relying solely on this patent would be undermined, and licensing revenue tied to the claims is effectively eliminated. The ruling also signals that Stryker’s prosecution strategy for this application failed to produce claims sufficiently distinguished from the prior art to survive inter partes scrutiny.
Patent rights extinguishedOsteoMed secures freedom to operate without the ‘751 patent overhead
OsteoMed’s successful defence of the unpatentability finding at the Federal Circuit level provides strong commercial clearance for its bone-plate product lines. The affirmance raises the bar significantly for Stryker to revive any equivalent claim scope through continuation or divisional filings, as the prior art landscape is now more clearly defined. Competitors across the orthopaedic fixation sector may similarly benefit from this cleared IP position.
FTO strengthened for challengerOrthopaedic fixation IP landscape shifts as key Stryker plate patent falls
The Federal Circuit’s affirmance of unpatentability in a bone-fixation plate case is a materially significant signal for the broader orthopaedic implant sector. Competitors developing inter-plate fixation systems should monitor this ruling’s prior-art characterisation — if available in the full opinion — as it may inform validity risks across a cluster of related patents. Device makers currently designing around US10993751B1 may now have more design freedom than previously assumed.
Sector-wide FTO implicationsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Stryker European Operations Holdings, LLC | Company | Orthopaedic device company — holder of US10993751B1 (bone-fixation plate implant)Search in Eureka ↗ |
| Defendant | OsteoMed, LLC | Company | OsteoMed, LLC — orthopaedic implant manufacturer; prevailing invalidity challengerSearch in Eureka ↗ |
| Plaintiff counsel | Sharon Hwang | Attorney | Counsel for Stryker European Operations Holdings, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McAndrews, Held & Malloy Ltd. | Law Firm | Representing Stryker European Operations Holdings, LLCSearch in Eureka ↗ |
| Defendant counsel | Jason Alexander Engel | Attorney | Counsel for OsteoMed, LLCSearch in Eureka ↗ |
| Defendant law firm | K&L Gates, LLP | Law Firm | Representing OsteoMed, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s per curiam order — ‘AFFIRMED’ — carries dispositive weight despite its brevity. Under Federal Circuit practice, affirmance means the panel reviewed the unpatentability determination under the applicable standard of review (de novo for legal conclusions; substantial evidence for fact-finding) and found no basis to disturb the outcome. The ‘Unpatentable’ basis of termination confirms the claims were found to lack patentability, most likely on obviousness or anticipation grounds. No remand was ordered, making the invalidity final at this level.
US10993751B1 — Orthopaedic bone-fixation plate implant
US10993751B1, filed under application number US17/143709, claims an orthopedic implant in the form of a plate designed to be fixed between two bone parts. This technology sits within the bone-fixation and fracture-repair segment of orthopaedic surgery — a market where plate geometry, fixation mechanism, and material composition are frequent battlegrounds for IP differentiation. The ‘B1’ designation indicates the patent issued without post-grant amendment, suggesting prosecution was relatively straightforward before the validity challenge arose.
Bone-fixation plate patents are commercially significant because they underpin both the surgical implant supply chain and licensing relationships between large OEMs and specialist manufacturers. Stryker’s assertion of this patent against OsteoMed — a focused orthopaedic implant company — suggests the claims were seen as relevant to a competitive product line. The Federal Circuit’s unpatentability affirmance now frees that claim space for the market, though it may catalyse Stryker to pursue narrower claim variations through continuation prosecution.
Should you run an FTO against US10993751B1?
R&D and product teams developing orthopaedic bone-fixation plate systems should note that US10993751B1 has been confirmed unpatentable by the Federal Circuit, removing it as an active blocking patent. However, Stryker’s broader US17/143709 patent family may include continuation applications with related claim scope that remain active. Any FTO analysis for inter-plate fixation devices should map the full family — not just the invalidated grant — before concluding the design space is clear.
PatSnap Eureka’s FTO Search Agent can identify all patent family members descended from application US17/143709, flag active continuation applications, and benchmark claim language against the prior art record established in this Federal Circuit proceeding. For orthopaedic device teams preparing a product launch or design-around strategy, running that family-level FTO now — before Stryker files further continuations — reduces downstream litigation exposure.
Run a freedom-to-operate analysis on US10993751B1 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit orthopaedic implant unpatentability appeals
Explore comparable Federal Circuit cases involving bone-fixation and orthopaedic implant patent validity challenges — same appellate level, overlapping technology domain.
What this case signals for the orthopaedic implant IP landscape
A Federal Circuit affirmance of unpatentability in bone-fixation technology reshapes the competitive IP calculus for the entire orthopaedic plate sector.
Cleared prior art creates near-term FTO opportunity for bone-plate manufacturers
With US10993751B1 confirmed unpatentable, manufacturers of inter-plate orthopaedic fixation devices should reassess their FTO positions. The Federal Circuit’s affirmance consolidates the prior art record. Any competitor previously designing around this patent may now operate with reduced litigation risk, though related continuation applications from Stryker warrant monitoring.
Stryker’s continuation filing strategy now faces a higher prior-art bar
Patent holders whose claims are found unpatentable at the Federal Circuit level typically face greater difficulty securing equivalent claim scope through continuation filings. Stryker’s prosecution team will need to demonstrate material claim differentiation from the prior art established in these proceedings. IP teams tracking Stryker’s US17/143709 family should watch for new continuation publications.
Stryker v OsteoMed — key questions answered
The Federal Circuit affirmed the unpatentability of US10993751B1, Stryker’s patent covering an orthopedic implant plate fixed between two bone parts. The court found no reversible error in the lower tribunal’s invalidity/cancellation determination, making the unpatentability final at this appellate level. The case was closed on 7 August 2025.
US10993751B1 (application US17/143709) is a patent held by Stryker European Operations Holdings, LLC covering an orthopedic implant in the form of a plate designed to be fixed between two bone parts. It falls within the bone-fixation and fracture-repair segment of orthopaedic surgery. The patent has been found unpatentable following Federal Circuit review.
An affirmance of unpatentability by the Federal Circuit means US10993751B1 can no longer be enforced against any party. Competitors manufacturing or developing inter-plate bone-fixation devices gain freedom to operate with respect to this specific patent. However, related continuation applications from Stryker under the same family (US17/143709) should still be monitored for active claim scope.
Stryker European Operations Holdings was represented by McAndrews, Held & Malloy Ltd., with attorney Sharon Hwang. OsteoMed, LLC was represented by K&L Gates, LLP, with attorney Jason Alexander Engel. The case was heard by the Court of Appeals for the Federal Circuit.
The affirmance closes off the Federal Circuit avenue for US10993751B1. Stryker’s theoretical remaining options are a petition for rehearing en banc or certiorari to the US Supreme Court, both of which face a very high success bar. Separately, Stryker may pursue continuation applications with differentiated claim language, though the prior art record established in these proceedings raises the prosecution bar considerably.
PatSnap Eureka searches patents and litigation data to answer instantly.